Navigation Links
Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting
Date:9/14/2009

VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria by Dr. Ulrich Costabel of the Ruhrlandklinik, Essen, Germany.

In order to assess the risk-benefit profile of pirfenidone in IPF patients, a comprehensive review of safety was conducted involving two Phase 3 trials (CAPACITY 1 and CAPACITY 2) and two open-label studies (RECAP and PIPF-002). RECAP is an on-going open-label extension study that enrolled 603 patients who completed CAPACITY. PIPF-002 is an on-going long-term, open-label study in 83 IPF patients.

The summary and conclusions from the safety analysis as presented at ERS were:

  • A comprehensive review of safety data from four clinical studies showed that treatment with pirfenidone was safe and generally well tolerated
  • In the CAPACITY studies:
  • The majority of adverse events (AE) were mild to moderate in nature and relatively few patients discontinued treatment due to adverse events.
  • A similar incidence of serious adverse events (SAE) was observed in the pirfenidone group relative to the placebo group
  • Fewer deaths were observed in the pirfenidone group relative to the placebo group and this difference was driven by a reduction in IPF-related deaths
  • GI and skin AE were more common in pirfenidone-treated patients and were generally mild to moderate, transient, and rarely led to treatment discontinuation
  • Transaminase (liver enzyme) elevations were slightly more common in the pirfenidone group, generally low-grade and without clinical sequ
    '/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... to settle into equilibriuma state of unchanging balance ... of non-equilibrium conditions where new possibilities lie. Non-equilibrium ... such as temperature fluctuations, freezing and melting, or ... body temperature, airplanes to fly, and the Earth ... even though these conditions exist naturally and are ...
(Date:7/24/2014)... 2014  CorMedix Inc. (NYSE MKT: CRMD), a ... products for the prevention and treatment of cardiorenal ... on July 18, 2014 from the NYSE MKT ... CorMedix plan to regain compliance with continued listing ... NYSE-MKT is continuing the Company,s listing and has ...
(Date:7/24/2014)... 1000 balances – 4 steps – One Recommendation: ... and expertly narrows down the mass of product choices ... terminals. , First, select the working environment, then ... instead) and define the accuracy – it’s really that ... the list to models that fit best with the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 As part ... numerous projects in the MENA region during 2014 with ... a preferred provider agreement with DZS to manage our ... region,” said Global VP of R&D and President of ... developed excellent operational practices with a focus on utilizing ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Medarex, Inc.,(Nasdaq: MEDX ) announced today that it ... Conference at 10:30 a.m. ET on Tuesday, January,8, 2008. ... available in the,Investor Relations section of the Medarex Web ... presentation will be available following the event., About ...
... PARK, N.C., Jan. 3 Chimerix, Inc., a,biotechnology ... Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined ... joining Chimerix, Dr. Frazer served as the Chief ... (previously,Biocure Medical) where he was responsible for the ...
... (Nasdaq: ONXX ) today announced that it ... January 7, at 11:30 a.m.,Pacific Time. Interested parties ... http://www.metameetings.com/webcasts/jpmorgan/healthcare08 , It is recommended ... order to,register and download any necessary software. For ...
Cached Biology Technology:Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
(Date:7/24/2014)... July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the ... randomized, active control Phase 3 study of Zerenex (ferric ... for the treatment of hyperphosphatemia in patients with end-stage ... binding and iRon delivery with FErric CiTrate in EsrD) ... the American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... over a 35 year period in which the human ... humans on declining animal numbers. This decline matters because ... crustaceans, slugs and worms bring to our day-to-day lives, ... nutrient cycling, water filtration and human health. , The ... UCL, Stanford and UCSB, focused on the demise of ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... of seven tropical forests around the world has revealed ... less common trees. The landmark study, conducted by 33 ... 27 issue of the journal Science, conclusively demonstrates that ... , Helene Muller-Landau, an assistant professor of ecology in ...
... Mellon University have discovered that our ears use the ... from babbling brooks to wailing babies. These results represent ... is encoded for transmission to the brain, according to ... "News and Views" editorial in the Feb. 23 issue ...
... of Pittsburgh Professor of Anthropology Jeffrey H. Schwartz and ... Jan. 30 in the New Anatomist journal, shows that ... to Schwartz's theory of evolution, originally explained in his ... of Species (John Wiley & Sons, 2000). , In ...
Cached Biology News:Underdogs in the understory: Study suggests nature favors rarer trees 2Carnegie Mellon scientists show brain uses optimal code for sound 2Carnegie Mellon scientists show brain uses optimal code for sound 3Pitt professor's theory of evolution gets boost from cell research 2Pitt professor's theory of evolution gets boost from cell research 3
ID clarifier: platform...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... is used for vertical electrophoresis applications. The cell accommodates ... L of running buffer. It includes the PROTEAN II ... kit, which contains accessories for use with 2.0 mm ... 2 sets of 20 x 20 cm glass plates, ...
Biology Products: